| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:15087269 | IVR | 0.1 mg/kg | 0.1 mg/kg | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Affects ovulation | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Affects ovulation | Reproductive endocrine-mediated perturbations | |
| PMID:17683461 | IVR | 0.0025 mg/kg | 0.0025 mg/kg | Reduced sperm counts | Reproductive endocrine-mediated perturbations |
| IVR | 0.0025 mg/kg | 0.0025 mg/kg | Decreased Alanine aminotransferase (ALT) levels | Hepatic endocrine-mediated perturbations | |
| IVR | 0.0025 mg/kg | 0.0025 mg/kg | Changes in morphology of seminiferous tubules | Reproductive endocrine-mediated perturbations | |
| PMID:19371625 | IVTH | 0.0000000025 - 0.000000005 M | 0.0000000025 - 0.000000005 M | Cancer phenotype | Endocrine-mediated cancer |
| IVTH | 0.0000000025 - 0.000000005 M | 0.0000000025 - 0.000000005 M | Affects intracellular signaling pathway | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.0000000025 - 0.000000005 M | 0.0000000025 - 0.000000005 M | Affects differentiation process | Developmental endocrine-mediated perturbations | |
| PMID:20637251 | IVR | 0.0002 mg/kg | 0.0002 mg/kg | Changes in mammary gland morphology | Reproductive endocrine-mediated perturbations |
| IVR | 0.02 mg/kg | 0.02 mg/kg | Changes in mammary gland morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Changes in mammary gland morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Hyperplasia in mammary glands | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Changes in mammary gland morphology | Reproductive endocrine-mediated perturbations | |
| PMID:21787672 | IVTH | 0.0000001 - 0.00005 M | 0.0000001 - 0.00005 M | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations |
| PMID:21803136 | IVTH | 0.00000001 - 0.0001 M | 0.0001 M | Decreased estradiol levels | Reproductive endocrine-mediated perturbations |
| IVTH | 0.00000001 - 0.0001 M | 0.0001 M | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00000001 - 0.0001 M | 0.0001 M | Decreased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00000001 - 0.0001 M | 0.0001 M | Decrease in cortisol levels | Neurological endocrine-mediated perturbations | |
| PMID:21907227 | IVTH | 0.00001 M | 0.00001 M | Affects oxidative phosphorylation | Metabolic endocrine-mediated perturbations |
| PMID:22240090 | IVR | 6.6 mg/kg/day | 6.6 mg/kg/day | Induced migration capability of tumor cells | Endocrine-mediated cancer |
| IVR | 1.3 mg/kg/day | 1.3 mg/kg/day | Induced migration capability of tumor cells | Endocrine-mediated cancer | |
| IVR | 3.9 mg/kg/day | 3.9 mg/kg/day | Induced migration capability of tumor cells | Endocrine-mediated cancer | |
| PMID:23291560 | IVR | 10 mg/L | 10 mg/L | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations |
| IVR | 40 mg/L | 40 mg/L | Affects expression of progesterone receptor (PR) | Reproductive endocrine-mediated perturbations | |
| IVR | 0.002 mg/L | - | No significant effects observed | - | |
| IVR | 40 mg/L | 40 mg/L | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations | |
| IVR | 40 mg/L | 40 mg/L | Affects fertility | Reproductive endocrine-mediated perturbations | |
| IVR | 40 mg/L | 40 mg/L | Affects implantation | Reproductive endocrine-mediated perturbations | |
| IVR | 40 mg/L | 40 mg/L | Affects uterine morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 4 mg/L | - | No significant effects observed | - | |
| PMID:24632555 | IVR | 3 mg/kg | 3 mg/kg | Alterations in thymocytes population | Immunological endocrine-mediated perturbations |
| IVR | 3 mg/kg | 3 mg/kg | Changes in B-cell populations | Immunological endocrine-mediated perturbations | |
| IVR | 3 mg/kg | 3 mg/kg | Thymus atrophy | Immunological endocrine-mediated perturbations | |
| PMID:27401186 | IVTH | 0.00000000001 - 0.00001 M | 0.00001 M | Cancer phenotype | Endocrine-mediated cancer |
| PMID:28396216 | IVTH | 0.00000000001 - 0.00001 M | 0.0000000001 - 0.00000001 M | Cancer phenotype | Endocrine-mediated cancer |
| PMID:28552778 | IVR | 0.04 mg/kg/day | 0.04 mg/kg/day | Affects folliculogenesis | Reproductive endocrine-mediated perturbations |
| IVR | 0.04 mg/kg/day | 0.04 mg/kg/day | Affects survival of germ cells | Reproductive endocrine-mediated perturbations | |
| IVR | 0.02 mg/kg/day | 0.02 mg/kg/day | Affects survival of germ cells | Reproductive endocrine-mediated perturbations | |
| IVR | 0.02 mg/kg/day | 0.02 mg/kg/day | Affects folliculogenesis | Reproductive endocrine-mediated perturbations | |
| PMID:28814190 | IVR | 0.2 mg/kg | - | No significant effects observed | - |
| IVR | 2 mg/kg | 2 mg/kg | Affects neuronal density | Neurological endocrine-mediated perturbations | |
| IVR | 2 mg/kg | 2 mg/kg | Decreased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 2 mg/kg | 2 mg/kg | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 2 mg/kg | 2 mg/kg | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations | |
| IVR | 2 mg/kg | 2 mg/kg | Increased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Increased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Affects neuronal density | Neurological endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Decreased LH levels | Reproductive endocrine-mediated perturbations | |
| PMID:28965971 | IVTH | 0.000000001 - 0.0000001 M | 0.000000001 - 0.0000001 M | Cancer phenotype | Endocrine-mediated cancer |
| PMID:29495557 | IVTH | 0.000000000001 M | 0.000000000001 M | Induce cancer metastasis | Endocrine-mediated cancer |
| IVTH | 0.000000000001 M | 0.000000000001 M | Induced migration capability of tumor cells | Endocrine-mediated cancer | |
| IVTH | 0.0000000001 M | 0.0000000001 M | Induced migration capability of tumor cells | Endocrine-mediated cancer | |
| PMID:30678243 | IVTH | 0.00000001 M | 0.00000001 M | Alters estrogen-responsive genes | Reproductive endocrine-mediated perturbations |
| IVTH | 0.00000001 M | 0.00000001 M | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.000001 M | 0.000001 M | Alters estrogen-responsive genes | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000000001 M | 0.000000001 M | Alters estrogen-responsive genes | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0000000001 M | - | No significant effects observed | - | |
| IVTH | 0.0000001 M | 0.0000001 M | Alters estrogen-responsive genes | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00000000001 M | - | No significant effects observed | - | |
| PMID:30953299 | IVTH | 0.001 mmol/L | 0.001 mmol/L | Affects cell metabolism | Metabolic endocrine-mediated perturbations |
| IVTH | 0.05 mmol/L | 0.05 mmol/L | Affects cell metabolism | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.0001 mmol/L | 0.0001 mmol/L | Affects cell metabolism | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.01 mmol/L | 0.01 mmol/L | Affects cell metabolism | Metabolic endocrine-mediated perturbations | |
| PMID:31058416 | IVR | 0.02 mg/kg | 0.02 mg/kg | Affects spermatogenesis in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 0.02 mg/kg | 0.02 mg/kg | Affects sperm motility in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.02 mg/kg | 0.02 mg/kg | Decreased testis weights in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.02 mg/kg | 0.02 mg/kg | Reduced sperm counts in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.04 mg/kg | 0.04 mg/kg | Increased liver weights in offspring | Developmental endocrine-mediated perturbations;Hepatic endocrine-mediated perturbations | |
| IVR | 0.04 mg/kg | 0.04 mg/kg | Reduced sperm counts in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.04 mg/kg | 0.04 mg/kg | Decreased testis weights in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.04 mg/kg | 0.04 mg/kg | Affects spermatogenesis in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.04 mg/kg | 0.04 mg/kg | Abnormal sperm morphology in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.04 mg/kg | 0.04 mg/kg | Affects sperm motility in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:31419471 | IVR | 0.04 mg/kg | 0.04 mg/kg | Decreased Alanine aminotransferase (ALT) levels | Hepatic endocrine-mediated perturbations |
| IVR | 0.04 mg/kg | 0.04 mg/kg | Affects spermatogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.02 mg/kg | 0.02 mg/kg | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.02 mg/kg | 0.02 mg/kg | Affects spermatogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.02 mg/kg | 0.02 mg/kg | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 0.04 mg/kg | 0.04 mg/kg | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.04 mg/kg | 0.04 mg/kg | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| PMID:33254391 | IVTH | 0.00003 M | 0.00003 M | Affects uterine morphology | Reproductive endocrine-mediated perturbations |
| PMID:38645625 | IVR | 1.5 mg/kg | 1.5 mg/kg | Decreased uterine weights | Reproductive endocrine-mediated perturbations |
| IVR | 0.5 - 1.5 mg/kg | 0.5 - 1.5 mg/kg | Causes inflammation | Immunological endocrine-mediated perturbations | |
| IVR | 0.5 - 1.5 mg/kg | 0.5 - 1.5 mg/kg | Affects uterine morphology | Reproductive endocrine-mediated perturbations | |
| PMID:38790905 | IVR | 0.1 mg/kg | 0.1 mg/kg | Affects ovulation | Reproductive endocrine-mediated perturbations |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Increased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Decreased Sex hormone-binding globulin (SHBG) levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Increased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Elevated insulin levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Elevated glucose levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| PMID:39252197 | IVTH | 0.00000001 M | 0.00000001 M | Cancer phenotype | Endocrine-mediated cancer |
| IVTH | 0.00000001 M | 0.00000001 M | Affects estrogen signaling | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00000001 M | 0.00000001 M | Affects developmental process | Developmental endocrine-mediated perturbations | |
| IVTH | 0.00000001 M | 0.00000001 M | Induce cancer metastasis | Endocrine-mediated cancer | |
| PMID:39306225 | IVTH | 0.000000025 M | 0.000000025 M | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations |
| IVTH | 0.000000005 - 0.000000025 M | 0.000000005 - 0.000000025 M | Affects intracellular signaling pathway | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.000000005 - 0.000000125 M | 0.000000005 - 0.000000125 M | Induced migration capability of tumor cells | Endocrine-mediated cancer | |
| IVTH | 0.000000001 - 0.000000125 M | 0.000000001 - 0.000000125 M | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.000000005 - 0.000000125 M | 0.000000005 - 0.000000125 M | Induce cancer metastasis | Endocrine-mediated cancer |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.